About

Pipeline

Business Development

Newsroom

Careers

Contact

中
B5.jpg b5_ph.jpg
Milestones

2024

  • Apr. 2024
    AffaMed Therapeutics Announces Appointment of Honggang Feng as Chief Executive Officer
  • Feb. 2024
    AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

2023

  • Oct. 2023
    AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery
  • Oct. 2023
    AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL
  • Sep. 2023
    AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
  • Sep. 2023
    AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA ® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
  • May. 2023
    AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA ® in Cataract Surgery Patients
  • May. 2023
    AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema
  • Apr. 2023
    AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
  • Mar. 2023
    AffaMed Technologies Announces TFDA Approval of MINI WELL, MINI WELL PROXA, MINI WELL TORIC and MINI 4 Ready IOLs for Cataract Treatment in Taiwan
  • Mar. 2023
    AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL®, the Progressive Extended Depth-of-Focus IOL

2022

  • Jul. 2022
    AIER and AffaMed Therapeutics Reach Strategic Cooperation in Boao LeCheng
  • May. 2022
    AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease
  • May. 2022
    AffaMed Therapeutics Announces Strategic Partnership with Primal Chemical to Market IOLs and DEXTENZA in Hong Kong and Macau
  • May. 2022
    AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau
  • Apr. 2022
    AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
  • Feb. 2022
    AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 – a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases
  • Jan. 2022
    AffaMed Therapeutics Doses First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA in China in Cataract Surgery Patients
  • Jan. 2022
    AffaMed Technologies Announces Successful Completion of First Patient Implantations of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in Boao, Hainan
  • Jan. 2022
    AffaMed Therapeutics Enters into a Licensing Agreement with Hanmi Pharmaceutical to Develop and Commercialize Risuteganib (Luminate®) as a First-In-Class Treatment for Intermediate Dry AMD Patients in Greater China

2021

  • Nov. 2021
    Supplemental New Drug Application for DEXTENZA Approved by FDA for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
  • Oct. 2021
    AffaMed Therapeutics' Joint Venture Launched in Beijing to Advance Industry-Leading Solutions for Cataract Surgery in Greater China
  • Sep. 2021
    AffaMed Therapeutics and Allgenesis Biotherapeutics Announce License Agreement for AG-73305 in Greater China Region
  • May. 2021
    AffaMed Therapeutics Announces Appointment of Vijay Karwal as Chief Financial Officer
  • Mar. 2021
    AffaMed Therapeutics and SIFI announce Joint Venture to serve Greater China Market
  • Mar. 2021
    Affamed Therapeutics announces completion of over US$170 million series B financing and appoints Dr. Ji Li as President and Board Member

2020

  • Oct. 2020
    AffaMed Therapeutics and Ocular Therapeutix announce license agreement and collaboration for DEXTENZA® and OTX-TIC in Asia
  • Oct. 2020
    AffaMed Therapeutics and EverInsight Therapeutics merged with Dayao Zhao, M.D., Ph.D. appointed as CEO
  • Jun. 2020
    EverInsight Therapeutics and VistaGen Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

2019

  • Aug. 2019
    EverInsight Therapeutics established
  • Feb. 2019
    AffaMed Therapeutics partners with Samsung Bioepis to develop and commercialize biosimilars in China
  • Feb. 2019
    AffaMed Therapeutics established